Please try another search
Welcure Drugs & Pharmaceuticals Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported revenue was INR 0.939 million compared to INR 2.37 million a year ago. Net loss was INR 1.75 million compared to net income of INR 1.02 million a year ago. Basic loss per share from continuing operations was INR 0.129 compared to basic earnings per share from continuing operations of INR 0.075 a year ago. Diluted loss per share from continuing operations was INR 0.129 compared to diluted earnings per share from continuing operations of INR 0.075 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -0.95 | -0.262 | 1.67 | |
Net Income | -0.332 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 14.06 | 15.29 | ||
Total Liabilities | 0.186 | 0.136 | ||
Total Equity | 15.15 | 15.15 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review